一项研究,旨在了解 Odronextamab 联合化疗的效果如何,以及与利妥昔单抗和化疗相比,在患有先前未经治疗的滤泡性淋巴瘤的成人参与者中的安全性如何 (OLYMPIA-2)
一项 3 期、开放标签、随机研究,旨在比较 Odronextamab (REGN1979)(一种抗 CD20x 抗 CD3 双特异性抗体)联合化疗与利妥昔单抗联合化疗在既往未经治疗的滤泡性淋巴瘤受试者中的疗效和安全性 (OLYMPIA- 2)
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study.
This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled).
The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study.
The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- The impact from the study drug on quality-of-life and ability to complete routine daily activities
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Beersheba、以色列、84101
- Soroka University Medical Center
-
Haifa、以色列、3109601
- Rambam Health Care Campus
-
Jerusalem、以色列、91200
- Hadassah Medical Center
-
Petah Tikva、以色列、49100
- Rabin Medical Center
-
Tel Aviv、以色列、64239
- The Tel Aviv Sourasky Medical Center
-
Tel Aviv、以色列、6971028
- Assuta Medical Centers
-
-
Jerusalem
-
Jerusalem、Jerusalem、以色列、9103102
- Shaare Zedek Medical Center
-
-
-
-
-
Kaohsiung City、台湾、83301
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City、台湾、80756
- Kaohsiung Medical University Hospital
-
New Taipei City、台湾、23561
- Taipei Medical University - Shuang Ho Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
Taipei、台湾、11490
- Tri-Service General Hospital
-
Taipei、台湾、11696
- Taipei Medical University Multipal Wan Fang University
-
-
-
-
-
Ankara、土耳其(türkiye)、06100
- Liv Hospital Ankara
-
Istanbul、土耳其(türkiye)、34365
- VKV American Hopital
-
Istanbul、土耳其(türkiye)、34418
- Istanbul University
-
Kayseri、土耳其(türkiye)、38039
- Erci̇yes Uni̇versi̇ty
-
Samsun、土耳其(türkiye)、55270
- Ondokuz Mayıs University
-
Zonguldak、土耳其(türkiye)、67100
- Zonguldak Bulent Ecevit University
-
-
Ankara
-
Mamak、Ankara、土耳其(türkiye)、06620
- Ankara University Faculty of Medicine
-
Yenimahalle、Ankara、土耳其(türkiye)、06200
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
Central Anatolia
-
Ankara、Central Anatolia、土耳其(türkiye)、06100
- Gazi University
-
-
Mersin
-
Mezitli、Mersin、土耳其(türkiye)、33200
- VM Medical Park Mersin Hospital
-
-
Serdivan
-
Sakarya、Serdivan、土耳其(türkiye)、54050
- Sakarya University
-
-
Suleymanpasa
-
Tekirdağ、Suleymanpasa、土耳其(türkiye)、59100
- Tekirdag Namik Kemal University Hospital
-
-
-
-
-
Vienna、奥地利、1090
- Universitatsklinik fur Kinder und Jungendheilkunde
-
Wels、奥地利、4600
- Klinikum Wels-Grieskirchen
-
-
Lower Austria
-
Sankt Pölten、Lower Austria、奥地利、3100
- Karl Landsteiner University Hospital St. Poelten
-
-
Styria
-
Graz、Styria、奥地利、8036
- Medical University of Graz
-
Leoben、Styria、奥地利、8700
- Landeskrankenhaus Hochsteiermark
-
-
Tyrol
-
Innsbruck、Tyrol、奥地利、6020
- Innsbruck Medical University
-
-
Upper Austria
-
Linz、Upper Austria、奥地利、4020
- Kepler University Hospital
-
-
-
-
-
Rio de Janeiro、巴西、20231050
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva
-
São Paulo、巴西、01323-903
- Hospital Alemao Oswaldo Cruz
-
São Paulo、巴西、08270-070
- Casa de Saude Santa Marcelina
-
São Paulo、巴西、01509-010
- AC Camargo Cancer Center
-
São Paulo、巴西、05403-000
- Clinical Hospital of Medicine School at Sao Paulo University
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、巴西、41253-900
- Hospital Sao Rafael
-
Salvador、Estado de Bahia、巴西、41950-640
- Ensino e Terapia de Inovacao Clinica Amo (Etica)
-
Salvador、Estado de Bahia、巴西、40050-410
- Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
-
-
Federal District
-
Brasília、Federal District、巴西、70200-730
- Hospital Sirio Libanes Brasilia
-
Brasília、Federal District、巴西、70390-140
- Instituto DOr de Pesquisa e Ensino Df Star
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、巴西、30380-472
- Instituto Mario Pena de Ensino Pesquisa e Inovacao
-
Uberlândia、Minas Gerais、巴西、38408-008
- Centro Oncologico do Triangulo (COT) - Uberlandia
-
-
Paraná
-
Curitiba、Paraná、巴西、81520-060
- Hospital Erasto Gaertner
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、巴西、59062-000
- Liga Norte Riograndense Contra o Cancer
-
-
Rio Grande do Sul
-
Bento Gonçalves、Rio Grande do Sul、巴西、95700-084
- Instituto Tacchini de Pesquisa em Saude
-
Passo Fundo、Rio Grande do Sul、巴西、99010-080
- Instituto do Cancer em Hospital Sao Vicente de Paulo
-
Porto Alegre、Rio Grande do Sul、巴西、90035-903
- Hospital de Clinicas de Porto Alegre
-
-
Santa Catarina
-
Joinville、Santa Catarina、巴西、89201-260
- Centro de Hematologia e Oncologia
-
Lages、Santa Catarina、巴西、88501-001
- Animi Unidade de Tratamento Oncologico Ltda
-
-
São Paulo
-
Barretos、São Paulo、巴西、14784-400
- Fundacao Pio XII Hospital de Amor
-
Jaú、São Paulo、巴西、17210-080
- Amaral Carvalho Hospital
-
Ribeirão Preto、São Paulo、巴西、14048-900
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
-
-
-
-
-
Kiel、德国、24116
- Stadtisches Krankenhaus Kiel
-
Neuss、德国、41462
- MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
-
-
-
-
-
Milan、意大利、20141
- Istituto Europeo di Oncologia
-
Milan、意大利、20162
- ASST Grande Ospedale Metropolitano Niguarda - Main Address
-
Milan、意大利、20122
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena、意大利、41124
- A.O.U. di Modena
-
Naples、意大利、80131
- Federico II University
-
Perugia、意大利、06132
- Azienda Ospedaliera di Perugia
-
Pisa、意大利、56126
- University of Pisa, Section of Hematology
-
Potenza、意大利、85100
- Azienda Ospedaliera Regionale San Carlo
-
Ravenna、意大利、48121
- UO Ematologia Ravenna
-
Reggio Emilia、意大利、42123
- Azienda Unita Sanitaria Locale Irccs Arcispedale Santa Maria Nuova
-
Rome、意大利、00161
- Azienda Osperdaliero-Universitaria Policlinico Umberto 1
-
Udine、意大利、33100
- Azienda Sanitaria Universitaria del Friuli Centrale
-
-
Forli-Cesena
-
Meldola、Forli-Cesena、意大利、47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
-
Piedmont
-
Turin、Piedmont、意大利、10137
- Azienda Ospedaliera Ordine Mauriziano Torino, Presidio Umberto I of Turin
-
-
Sicily
-
Palermo、Sicily、意大利、90127
- Azienda Ospedaliera Universitario Policlinico Palermo
-
-
-
-
North Central Czech Republic
-
Hradec Králové、North Central Czech Republic、捷克语、50005
- University Hospital Hradec Kralove
-
-
South Moravian
-
Brno、South Moravian、捷克语、62500
- University Hospital Brno
-
-
-
-
Las Condes
-
Santiago、Las Condes、智利、7620157
- Hospital Clinico Universidad de Los Andes
-
-
Santiago Metropolitan
-
Santiago、Santiago Metropolitan、智利、7560907
- Centro Oncologia de Precision Universidad Mayor
-
Santiago、Santiago Metropolitan、智利、7580206
- Inmunocel
-
Santiago、Santiago Metropolitan、智利、7550000
- Pontificia Universidad Catolica de Chile
-
-
-
-
-
Brussels、比利时、1000
- Institut Jules Bordet
-
Liège、比利时、4000
- Centre Hospitalier Regional de la Citadelle
-
-
Oost-Vlaanderen
-
Ghent、Oost-Vlaanderen、比利时、9000
- Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
-
Sint-Niklaas、Oost-Vlaanderen、比利时、9100
- Verenigde Ziekenhuizen van Waas en Durme
-
-
West-Vlaanderen
-
Bruges、West-Vlaanderen、比利时、8000
- Algemeen Ziekenhuis St Jan Brugge Oostende Av
-
Kortrijk、West-Vlaanderen、比利时、8500
- AZ Groeninge
-
-
-
-
-
Grenoble、法国、38043
- Centre Hospitalier Universitaire de Grenoble
-
Le Puy-en-Velay、法国、43012
- Centre Hospitalier Emile Roux
-
Lens、法国、62300
- Centre Hospitalier de Lens (Centre Hospitalier Dr Schaffner dLens)
-
Paris、法国、75010
- Hopital Saint Louis
-
Pessac、法国、33600
- Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Sud - Hôpital Haut Lévêque
-
Saint-Etienne、法国、42055
- CHU de Saint-Etienne
-
Saint-Nazaire、法国、44600
- Centre Hospitalier de Saint Nazaire
-
-
Alpes Maritimes
-
Cannes、Alpes Maritimes、法国、06400
- Cannes Hospital (Centre Hospitalier Cannes Simone Veil)
-
-
Centre-Val de Loire
-
Tours、Centre-Val de Loire、法国、37044
- CHRU de Tours
-
-
Gard
-
Nîmes、Gard、法国、30029
- Institut de Cancerologie du Gard
-
-
New Aquitaine
-
Mont-de-Marsan、New Aquitaine、法国、40024
- Centre Hospitalier de Mont-de-Marsan
-
-
Pays de la Loire Region
-
Nantes、Pays de la Loire Region、法国、44093
- Nantes University Hospital
-
-
Pontoise
-
Cergy-Pontoise、Pontoise、法国、95300
- The Novo Hospital North West Val Deoise
-
-
Île-de-France Region
-
Argenteuil、Île-de-France Region、法国、95100
- Hopital Victor Dupouy Argenteuil
-
-
-
-
-
Bydgoszcz、波兰、85-168
- Szpital Uniwersytecki Nr2 Bydgoszcz
-
Gdansk、波兰、80-952
- Uniwersyteckie Centrum Kliniczne, Building of the Non-Invasive Medicine Center
-
Katowice、波兰、40-519
- Pratia Onkologia Katowice
-
Lodz、波兰、93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
-
Lublin、波兰、20-954
- Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
-
Warsaw、波兰、02781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
-
Wałbrzych、波兰、58-300
- Szpital Szpecjalistyczny w Walbrzychu
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、波兰、30-510
- Matopolskie Centrum Medyczne S.C.
-
-
Wielkopolska
-
Skorzewo、Wielkopolska、波兰、60185
- Aidport Sp. z o.o.
-
-
-
-
-
Khon Kaen、泰国、40002
- Khon Kaen University
-
-
Krung Thep Maha Nakhon [Bangko]
-
Bangkok、Krung Thep Maha Nakhon [Bangko]、泰国、10330
- Chulalongkorn University
-
-
-
-
New South Wales
-
Liverpool、New South Wales、澳大利亚、2170
- Liverpool Hospital
-
Waratah、New South Wales、澳大利亚、2298
- Calvary Mater Newcastle
-
-
Queensland
-
Benowa、Queensland、澳大利亚、4217
- Pindara Private Hospital
-
-
-
-
Florida
-
Plantation、Florida、美国、33322
- Boca Raton Clinical Research (BRCR) Global
-
-
Indiana
-
Noblesville、Indiana、美国、46062
- Investigative Clinical Research of Indiana
-
-
Kansas
-
Wichita、Kansas、美国、67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- University of Kentucky
-
-
Michigan
-
Detroit、Michigan、美国、48202
- Henry Ford Health System
-
Grand Rapids、Michigan、美国、49503
- Cancer and Hematology Centers of Western Michigan
-
-
Texas
-
Houston、Texas、美国、77030
- Center for Oncology and Blood Disorders
-
-
Utah
-
Ogden、Utah、美国、84405
- Community Cancer Trials of Utah
-
-
Wisconsin
-
Waukesha、Wisconsin、美国、53188
- Prohealth Care Inc
-
-
-
-
-
Aberdeen、英国、AB25 2ZN
- NHS Grampian: Aberdeen Royal Infirmary
-
-
Cornwall
-
Truro、Cornwall、英国、TR1 3LJ
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
-
-
London
-
Uxbridge、London、英国、UB8 3NN
- The Hillingdon Hospitals NHS Foundation Trust
-
-
West Midlands
-
Birmingham、West Midlands、英国、B15 2SY
- University Hospitals Birmingham NHS Foundation Trust
-
-
-
-
-
Lugo、西班牙、27003
- Hospital Universitario Lucus Augusti
-
Madrid、西班牙、28027
- Clinica Universidad de Navarra - Madrid
-
Madrid、西班牙、28034
- Hospital Universitario Ramon y Cajal
-
Madrid、西班牙、28041
- Hospital Universitario 12 de Octubre
-
Madrid、西班牙、28031
- Hospital Universitario Infanta Leonor
-
Madrid、西班牙、28040
- Hospital Universitario Fundacion Jimenez Diaz
-
Ourense、西班牙、32005
- Complexo Hospitalario Universitario de Ourense
-
Pamplona、西班牙、31008
- Clinica Universidad de Navarra- Pamplona
-
Salamanca、西班牙、37007
- Hospital Universitario de Salamanca
-
Seville、西班牙、41009
- Hospital Universitario Virgen Macarena
-
Valencia、西班牙、46009
- Instituto Valenciano de Oncologia
-
Valencia、西班牙、46010
- Hospital Clinico Universitario de Valencia
-
-
Andalusia
-
Seville、Andalusia、西班牙、41013
- Hospital Universitario Virgen del Rocio
-
-
Barcelona
-
Sabadell、Barcelona、西班牙、08208
- Parc Tauli Sabadell Hospital Universitari
-
Terrassa、Barcelona、西班牙、08221
- Hospital Universitari Mutua Terrassa
-
-
Bizkaia
-
Barakaldo、Bizkaia、西班牙、48903
- Cruces University Hospital (Hospital Universitario Cruces)
-
-
Madrid
-
Majadahonda、Madrid、西班牙、28222
- Hospital Universitario Puerta de Hierro - Majadahonda
-
Pozuelo de Alarcón、Madrid、西班牙、28223
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona、Navarre、西班牙、31008
- Hospital Universitario de Navarra
-
-
Principality of Asturias
-
Oviedo、Principality of Asturias、西班牙、33011
- Hospital Universitario Central de Asturias
-
-
Valencia
-
Alicante、Valencia、西班牙、03010
- Hospital General Universitario Doctor Balmis Alicante
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV
- For Part 1A: previously untreated participants who have Follicular Lymphoma International Prognostic Index (FLIPI)-1 score of 3 to 5, or R/R FL
- For Part 1B: previously untreated participants who have FLIPI-1 score of 3 to 5
- For Part 2: previously untreated participants who have FLIPI-1 score of 0 to 5
-
Have measurable disease on cross sectional imaging documented by diagnostic computed tomography [CT], or magnetic resonance imaging [MRI] imaging, as described in the protocol
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
-
Adequate bone marrow and hepatic function.
Key Exclusion Criteria:
- Participants with central nervous system lymphoma or leptomeningeal lymphoma
- Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
- Participants with Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), grade 3b follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma
- Recent major surgery and history or organ transplantation
- A malignancy other than NHL unless the participant is adequately and definitively treated and any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Odronextamab + Chemotherapy
Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (Odro) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL. |
Administered by intravenous (IV) infusion
其他名称:
Administered by IV infusion
其他名称:
Administered by IV infusion
其他名称:
Administered orally (PO)
其他名称:
|
|
有源比较器:Rituximab + Chemotherapy
In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance. |
Administered by intravenous (IV) infusion
其他名称:
Administered by IV infusion
其他名称:
Administered by IV infusion
其他名称:
Administered orally (PO)
其他名称:
Administered by IV infusion, or subcutaneous (SC)
其他名称:
Administered by IV infusion
其他名称:
|
|
实验性的:Odronextamab + Chemotherapy + Maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy [CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)], followed by odronextamab monotherapy maintenance. |
Administered by intravenous (IV) infusion
其他名称:
Administered by IV infusion
其他名称:
|
|
实验性的:Odronextamab + Chemotherapy + No maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance. |
Administered by intravenous (IV) infusion
其他名称:
Administered by IV infusion
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy
大体时间:Up to 35 days
|
Part 1, DLT period |
Up to 35 days
|
|
Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapy
大体时间:Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Severity of TEAEs of odronextamab in combination with chemotherapy
大体时间:Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)
大体时间:Up to 30 months
|
Part 2 |
Up to 30 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
CR30 as assessed by local investigator
大体时间:Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Incidence of TEAEs
大体时间:Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Severity of TEAEs
大体时间:Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Change in Patient Global Impression of Severity (PGIS)
大体时间:Up to 5 years
|
Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe). |
Up to 5 years
|
|
Change in Patient Global Impression of Change (PGIC)
大体时间:Up to 5 years
|
Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse. |
Up to 5 years
|
|
BOR as assessed by ICR
大体时间:Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered with chemotherapy
大体时间:Up to 30 months
|
Part 1, Maintenance period and Part 2, Induction period |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered as monotherapy
大体时间:Up to 30 months
|
Part 1 and Part 2, Maintenance period |
Up to 30 months
|
|
Incidence of anti-odronextamab antibodies (ADAs)
大体时间:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Titers of ADAs to odronextamab
大体时间:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Incidence of neutralizing antibodies (NAb) to odronextamab
大体时间:Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Best overall response (BOR) as assessed by the investigator
大体时间:Up to 30 months
|
Part 1, end of Induction period and end of Maintenance period |
Up to 30 months
|
|
Progression free survival (PFS) as assessed by ICR
大体时间:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported physical functioning scale scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30)
大体时间:Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
PFS as assessed by local investigator
大体时间:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Event-free survival (EFS) as assessed by ICR
大体时间:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
EFS as assessed by local investigator
大体时间:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
BOR as assessed by local investigator
大体时间:Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Duration of response (DOR) assessed by ICR
大体时间:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
DOR as assessed by local investigator
大体时间:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Time to next anti-lymphoma treatment (TTNT)
大体时间:Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported health related quality of life (HRQoL) as measured by EORTC-QLQ-C30
大体时间:Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in cancer disease as measured by EORTC-QLQ-C30
大体时间:Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in treatment related symptoms as measured by EORTC-QLQ-C30
大体时间:Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in patient-reported lymphoma disease as measured by the Lymphoma Subscale of the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS)
大体时间:Up to 5 years
|
Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in treatment-related symptoms as measured by the FACT-LymS
大体时间:Up to 5 years
|
Part 2 The FACT-LymS includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in patient-reported general health status per EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
大体时间:Up to 5 years
|
Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Up to 5 years
|
|
Change in patient-reported treatment side effects burden per Functional Assessment of Cancer Therapy-General Global Population Item 5 (FACT-G GP5)
大体时间:Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
|
Change in score of the FACT-G GP5 item in the patient population
大体时间:Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
合作者和调查者
调查人员
- 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 病理过程
- 肿瘤
- 疾病属性
- 免疫系统疾病
- 组织学类型的肿瘤
- 淋巴系统疾病
- 淋巴增生性疾病
- 免疫增生性疾病
- 淋巴瘤,非霍奇金
- 淋巴瘤
- 病理状况、体征和症状
- 半身和淋巴疾病
- 复发
- 淋巴瘤,滤泡性
- 氨基酸,肽和蛋白质
- 蛋白质
- 有机化学品
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- 生物碱
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 糖苷
- 吲哚
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 怀孕
- 怀孕
- 类固醇
- 融合环化合物
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 疗法
- 妊娠二培养子
- VINCA生物碱
- Secologanin色素生物碱
- 吲哚生物碱
- 吲哚衍生物
- 吲哚王
- 蒽环类动物
- 萘烯
- 氨基糖苷
- 抗体,单克隆,鼠的衍生
- Daunorubicin
- 泼尼松龙
- 利妥昔单抗
- 强的松
- 环磷酰胺
- 阿霉素
- 长春新碱
- 甲基强的松龙
其他研究编号
- R1979-ONC-2075
- 2022-502113-28-00 (其他标识符:EUCT Number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD 共享时间框架
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共享访问标准
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.